腾盛博药-B (02137)2025年度业绩：实现0.018605亿元收入，亏损显著收窄

公告速递

Mar 19

腾盛博药-B (02137) 截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。

报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。财务成本小幅下降至人民币0.001961亿元，其他收益及亏损净额则由上一年度的人民币-0.197665亿元转为本年度的人民币0.014761亿元。

期末现金及银行存款（含定期存款及受限制银行结余）降至人民币19.41亿元（上一年度为人民币24.134亿元），流动资产为人民币19.30256亿元，非流动资产为人民币3.97001亿元，总资产合计人民币23.27257亿元。于2025年12月31日，负债合计人民币0.03888亿元，净资产约人民币23.23369亿元（上一年度为人民币26.0608亿元）。流动比率由3118%上升至6073%，资产负债比率在本报告期及上一报告期均不适用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173598131"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173598131\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173598131?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-19 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173598131","market":"hk","top_or_hot":-1,"title":"腾盛博药-B (02137)2025年度业绩：实现0.018605亿元收入，亏损显著收窄","media":"公告速递","content":"<p>腾盛博药-B (02137) 截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。</p>\n<p>报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。财务成本小幅下降至人民币0.001961亿元，其他收益及亏损净额则由上一年度的人民币-0.197665亿元转为本年度的人民币0.014761亿元。</p>\n<p>期末现金及银行存款（含定期存款及受限制银行结余）降至人民币19.41亿元（上一年度为人民币24.134亿元），流动资产为人民币19.30256亿元，非流动资产为人民币3.97001亿元，总资产合计人民币23.27257亿元。于2025年12月31日，负债合计人民币0.03888亿元，净资产约人民币23.23369亿元（上一年度为人民币26.0608亿元）。流动比率由3118%上升至6073%，资产负债比率在本报告期及上一报告期均不适用。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>腾盛博药-B (02137)2025年度业绩：实现0.018605亿元收入，亏损显著收窄</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n腾盛博药-B (02137)2025年度业绩：实现0.018605亿元收入，亏损显著收窄\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-03-19 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>腾盛博药-B (02137) 截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。</p>\n<p>报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。财务成本小幅下降至人民币0.001961亿元，其他收益及亏损净额则由上一年度的人民币-0.197665亿元转为本年度的人民币0.014761亿元。</p>\n<p>期末现金及银行存款（含定期存款及受限制银行结余）降至人民币19.41亿元（上一年度为人民币24.134亿元），流动资产为人民币19.30256亿元，非流动资产为人民币3.97001亿元，总资产合计人民币23.27257亿元。于2025年12月31日，负债合计人民币0.03888亿元，净资产约人民币23.23369亿元（上一年度为人民币26.0608亿元）。流动比率由3118%上升至6073%，资产负债比率在本报告期及上一报告期均不适用。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"","article_id":"1173598131","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173598131","pubTimestamp":1773918580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"腾盛博药-B  截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02137":"腾盛博药-B"},"translate_title":"Tengsheng Boyao-B (02137) 2025 Annual Results: Achieved Revenue of 0.018605 Million Yuan, Loss Significantly Narrowed","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"腾盛博药-B (02137) 截至2025年12月31日止年度首次录得收入人民币0.018605亿元，主要来自许可费收入及技术转移协议信用取得的款项。同期年内亏损为人民币0.224067亿元，较上一年度的人民币0.512381亿元减少人民币0.288314亿元。\n报告期内，研究开支由上一年度的人民币0.249847亿元降至人民币0.212899亿元，主要源于第三方合约成本及雇员成本降低。行政开支则由人民币0.153155亿元降至人民币0.10945亿元，主要与员工成本及专业费用减少有关。财务成本小幅下降至人民币0.001961亿元，其他收益及亏损净额则由上一年度的人民币-0.197665亿元转为本年度的人民币0.014761亿元。\n期末现金及银行存款（含定期存款及受限制银行结余）降至人民币19.41亿元（上一年度为人民币24.134亿元），流动资产为人民币19.30256亿元，非流动资产为人民币3.97001亿元，总资产合计人民币23.27257亿元。于2025年12月31日，负债合计人民币0.03888亿元，净资产约人民币23.23369亿元（上一年度为人民币26.0608亿元）。流动比率由3118%上升至6073%，资产负债比率在本报告期及上一报告期均不适用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}